Cole Korponay*
Edited by Paige Omura and Grant A. Knappe
Article | Aug. 29 2022
DOI: 10.38105/spr.nei10sp0hh/
Highlights
- An evolving understanding of the relationship between drugs and the brain is contributing to a paradigm shift in drug policy, defined by measures to help keep individuals with addiction alive as the long path toward recovery takes course
- Significant harm-reduction potential exists in increasing access to medication assisted treatment (MAT) – the most effective approach for managing opioid use disorder, but which less than 20% of affected individuals in the U.S. receive
- Developments in the neuroscience of targeted brain stimulation and brain-based risk prediction represent novel treatment and prevention strategies on the near-horizon
Article Summary
*Email: ckorponay@mclean.harvard.edu
Open Access
This MIT Science Policy Review article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/.
Cole Korponay
Department of Psychiatry, Harvard Medical School, Cambridge, MA
